Omnes, Bpifrance back €12m Series A round for cancer treatment side-effect drug developer AlgoTherapeutix
French biotech company AlgoTherapeutix has raised €12m in a Series A round led by Bpifrance through its InnoBio 2 fund alongside co-investor Omnes.
